slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 33,931-33,960
Pages 2,019
Rows per page 30
Component
33,931-33,960 of 60,557
48
Includes detailed footnotes explaining adjustments for discontinued products, non-recurring expenses, and FX gains/losses.Getty | SPAC Presentation Deck | 52 slides · Getty Images
Pitch deck Investment bank 1 hit
49
The table provides a detailed breakdown of adjustments including discontinued products, D&A, interest, taxes, and various non-recurring items.Getty | SPAC Presentation Deck | 52 slides · Getty Images
Pitch deck Investment bank 1 hit
13
The slide combines team bios with investor logos and diversity statistics.Grove | SPAC Presentation Deck | 59 slides · Grove
Pitch deck Investment bank Beat · Early Struggles1 hit
16
The slide uses a comparison table to demonstrate product efficacy against leading competitors.Grove | SPAC Presentation Deck | 59 slides · Grove
Pitch deck Investment bank Beat · Rising SuccessLoop · Why Now1 hit
28
The slide uses a checkmark/cross comparison matrix to highlight competitive advantages.Grove | SPAC Presentation Deck | 59 slides · Grove
Pitch deck Investment bank Beat · Rising Success1 hit
51
The table shows a transition from high growth/high loss to profitability targets.Grove | SPAC Presentation Deck | 59 slides · Grove
Pitch deck Investment bank Beat · Ultimate Achievement1 hit
57
The table shows adjustments for interest, taxes, D&A, preferred stock warrants, and stock-based compensation.Grove | SPAC Presentation Deck | 59 slides · Grove
Pitch deck Investment bank Beat · Ultimate Achievement1 hit
08
The slide outlines the methodology and timeline for reporting financed emissions in line with NZBA guidelines and PCAF standards.HSBC | ESG Presentation Deck | 10 slides · HSBC
Conference presentation Investor relations Beat · New Bliss1 hit
02
The slide uses a grouped bar chart to show historical revenue and gross profit trends alongside a detailed financial table.Hypebeast | Results Presentation Deck | 12 slides · Hypebeast
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
Data is unaudited and presented in HK$'000.Hypebeast | Results Presentation Deck | 12 slides · Hypebeast
Conference presentation Investor relations 1 hit
10
Includes percentage change column.Hypebeast | Results Presentation Deck | 12 slides · Hypebeast
Conference presentation Investor relations 1 hit
11
Data is in HK$'000. Figures in parentheses indicate negative values.Hypebeast | Results Presentation Deck | 12 slides · Hypebeast
Conference presentation Investor relations 1 hit
12
Hypebeast | Results Presentation Deck | 12 slidesHypebeast | Results Presentation Deck | 12 slides · Hypebeast
Conference presentation Investor relations 1 hit
15
The 2021 column is highlighted with a box to emphasize current status.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · Problem & Complication1 hit
24
Includes a footnote explaining the 2020 COVID-19 related adjustments.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · WhatLoop · Golden Circle1 hit
26
The chart illustrates a piecewise linear function for bonus payout based on performance percentage.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · WhatLoop · Golden Circle1 hit
29
The slide highlights a shift towards ESG targets and adjusted financial criteria for executive compensation.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · WhatLoop · Golden Circle1 hit
78
The slide outlines the specific financial and operational constraints for the company's share buyback program.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
79
The table lists various financial authorizations, all of which are currently marked as 'Unused'.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
09
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · InterestLoop · Logic Chain1 hit
12
The slide uses a Gantt-chart style layout to show the progression of various drug programs from discovery through clinical phases.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · DesireLoop · Logic Chain1 hit
21
Includes a mechanism of action diagram, a market data table, and a summary of limitations of current therapies.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
24
The left chart is a volcano plot showing selectivity; the right chart is a dose-response curve comparing the degrader to a kinase inhibitor.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
25
Includes bar charts for degradation and physiological markers, plus a line chart for EAE clinical scores.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
27
SAD = Single Ascending Dose; MAD = Multiple Ascending Dose.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
28
The chart displays mean (± SE) percent IRAK4 change from baseline. P-values are relative to placebo.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
31
The table uses checkmarks to indicate inhibition activity across different targets and stimuli.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
32
SAD = Single Ascending Dose; AE = Adverse Event; SAE = Serious Adverse Event.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
33
The slide compares Day 1 and Day 14 PK profiles, highlighting the accumulation and steady-state achievement.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
35
Data shows high efficacy at lower doses with a plateau effect observed at 100mg.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit